**DEPARTMENT OF HEALTH & HUMAN SERVICES** Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-829/S-014

Merck Research Laboratories
P.O. Box 2000 – RY33-720
Rahway, New Jersey 07065

Attention: David Altarac, MD, MPA
Director, Regulatory Affairs

Dear Dr. Altarac:

Please refer to your supplemental new drug application dated April 25, 2001, received April 26, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Singulair (Montelukast Sodium) Tablets.

This supplemental new drug application provides for changes in the "complimentary" carton labeling for the bottle of seven (10-mg) tablets.

We have completed the review of this supplemental application and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (immediate container and carton labels submitted April 25, 2001).

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavyweight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-829/S-014." Approval of this submission by FDA is not required before the labeling is used.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Dr. Craig Ostroff, Regulatory Management Officer, at (301) 827-5585.

Sincerely,

*{See appended electronic signature page}*

Robert J. Meyer, M.D.
Director
Division of Pulmonary and Allergy Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

---

**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**

---

/s/

---

Robert Meyer

10/26/01 04:31:25 PM